Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy – Endpoints News
Endpoints News |
Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy
Endpoints News Solid Biosciences has come up with a $50 million crossover round that would appear to be positioning the company for an IPO as it advances a gene therapy for Duchenne muscular dystrophy into the clinic. Founded by Duchenne dad — and former JP … Biogen-backed Duchenne firm Solid Biosciences raises $50MBoston Business Journal Solid Biosciences Raises up to $50 Million in Series C Financing …Business Wire (press release) |
Fox News |
Novartis says US regulator grants speedy review of CAR–T cell therapy
Fox News ZURICH – Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker’s CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia. The move would keep … Novartis gets speedy review for CAR–T cell therapyPharmaTimes Novartis Makes Plans For Its Cancer-Killing T CellsForbes Novartis announces first CAR–T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted …Yahoo Finance STAT –pharmaphorum –MedCity News all 17 news articles » |
Medical Xpress |
Method identified to boost detection of highly cancerous stem cells
Medical Xpress Cancer stem cells (CSCs) escape from 5-aminolevulinic acid (5-ALA)-based photodynamic detection (PDD) (upper panel). An iron chelator deferoxamine (DFO) enhances accumulation in CSCs of PpIX from 5-ALA, which will facilitate the elimination …more. |
Xconomy |
Tango Launched with $55M to Exploit Sequencing and CRISPR Target Discovery
Genetic Engineering & Biotechnology News Third Rock Ventures has launched a new cancer drug discovery and development company, Tango Therapeutics, with a $55 million Series A investment. The new firm is exploiting a platform that combines sequencing and CRISPR-based screening to identify … Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A InvestmentBusiness Wire (press release) New Cambridge biotech Tango aims to make cancer its own worst enemyBoston Business Journal |
|
Inovio and Collaborators Receive NIH Grantto Evaluate HIV Immunotherapy PENNVAX-GPs Abilityto Induce …
EconoTimes Development of Inovio’s PENNVAX-GP immunotherapy, which widely targets multiple major clades of HIV — providing global coverage — has been funded through a $25 million NIAID contract awarded to Inovio and its collaborators. In addition, Inovio and … |